About this scholarly article

Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma by Martinez-Lopez, J; Sanchez-Vega, B; Barrio, S; Cuenca, I; Ruiz-Heredia, Y; Alonso, R; Rapado, I; Marin, C; Cedena, M-T; Paiva, B; Puig, N; Mateos, M-V; Ayala, R; Hernández, M-T; Jimenez, C; Rosiñol, L; Martínez, R; Teruel, A-I; Gutiérrez, N; Martin-Ramos, M-L; Oriol, A; Bargay, J; Bladé, J; San-Miguel, J; Garcia-Sanz, R; Lahuerta, J-J is a scholarly article available to read on EtoBox.

Author

Martinez-Lopez, J; Sanchez-Vega, B; Barrio, S; Cuenca, I; Ruiz-Heredia, Y; Alonso, R; Rapado, I; Marin, C; Cedena, M-T; Paiva, B; Puig, N; Mateos, M-V; Ayala, R; Hernández, M-T; Jimenez, C; Rosiñol, L; Martínez, R; Teruel, A-I; Gutiérrez, N; Martin-Ramos, M-L; Oriol, A; Bargay, J; Bladé, J; San-Miguel, J; Garcia-Sanz, R; Lahuerta, J-J

Publisher

Nature Publishing Group; Springer Science and Business Media LLC (ISSN 0887-6924)

Published

2017